The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.’s BMY investigational oral therapy mezigdomide in combination with carfilzomib ...

Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating ...

The MonumenTAL-6 results add to the growing body of evidence touting Talvey and Tecvayli’s use in earlier multiple myeloma treatment lines.

Johnson & Johnson has announced positive topline results from the phase 3 MonumenTAL‑6 study, which evaluated TECVAYLI and ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Treatment for relapsed or refractory multiple myeloma includes anti-CD38 antibodies, immunomodulating agents, CAR-T cell therapies, and bispecific antibodies, with evolving options enhancing patient ...

OPN-6602 received orphan drug designation for relapsed or refractory multiple myeloma, highlighting its therapeutic potential. The FDA's orphan drug designation offers benefits like tax credits and ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

The efficacy of teclistamab, a bispecific antibody targeting B-cell maturation antigen and CD3, as early-line monotherapy in relapsed or refractory multiple myeloma is unclear. We randomly assigned ...

Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today ...